|
1
|
Porter PL: Global trends in breast cancer
incidence and mortality. Salud Publica Mex. 51(Suppl 2): s141–s146.
2009. View Article : Google Scholar
|
|
2
|
Yang L, Pang Y and Moses HL: TGF-beta and
immune cells: an important regulatory axis in the tumor
microenvironment and progression. Trends Immunol. 31:220–227. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Smith AL, Robin TP and Ford HL: Molecular
pathways: targeting the TGF-β pathway for cancer therapy. Clin
Cancer Res. 18:4514–4521. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Derynck R, Akhurst RJ and Balmain A:
TGF-beta signaling in tumor suppression and cancer progression. Nat
Genet. 29:117–129. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Reeves R: Nuclear functions of the HMG
proteins. Biochim Biophys Acta. 1799:3–14. 2010. View Article : Google Scholar
|
|
6
|
Resar LM: The high mobility group A1 gene:
transforming inflammatory signals into cancer? Cancer Res.
70:436–439. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fusco A and Fedele M: Roles of HMGA
proteins in cancer. Nat Rev Cancer. 7:899–910. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ben-Porath I, Thomson MW, Carey VJ, et al:
An embryonic stem cell-like gene expression signature in poorly
differentiated aggressive human tumors. Nat Genet. 40:499–507.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chou BK, Mali P, Huang X, et al: Efficient
human iPS cell derivation by a non-integrating plasmid from blood
cells with unique epigenetic and gene expression signatures. Cell
Res. 21:518–529. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Karp JE, Smith BD, Resar LS, et al: Phase
1 and pharmacokinetic study of bolus-infusion flavopiridol followed
by cytosine arabinoside and mitoxantrone for acute leukemias.
Blood. 117:3302–3310. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nelson DM, Joseph B, Hillion J, Segal J,
Karp JE and Resar LM: Flavopiridol induces BCL-2 expression and
represses oncogenic transcription factors in leukemic blasts from
adults with refractory acute myeloid leukemia. Leuk Lymphoma.
52:1999–2006. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schuldenfrei A, Belton A, Kowalski J, et
al: HMGA1 drives stem cell, inflammatory pathway, and cell cycle
progression genes during lymphoid tumorigenesis. BMC Genomics.
12(549): 2011
|
|
13
|
Belton A, Gabrovsky A, Bae YK, et al:
HMGA1 induces intestinal polyposis in transgenic mice and drives
tumor progression and stem cell properties in colon cancer cells.
PLoS One. 7:e300342012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shah SN and Resar LM: High mobility group
A1 and cancer: potential biomarker and therapeutic target. Histol
Histopathol. 27:567–579. 2012.PubMed/NCBI
|
|
15
|
Abe N, Watanabe T, Masaki T, et al:
Pancreatic duct cell carcinomas express high levels of high
mobility group I(Y) proteins. Cancer Res. 60:3117–3122.
2000.PubMed/NCBI
|
|
16
|
Chiappetta G, Tallini G, De Biasio MC, et
al: Detection of high mobility group I HMGI(Y) protein in the
diagnosis of thyroid tumors: HMGI(Y) expression represents a
potential diagnostic indicator of carcinoma. Cancer Res.
58:4193–4198. 1998.PubMed/NCBI
|
|
17
|
Chiappetta G, Manfioletti G, Pentimalli F,
et al: High mobility group HMGI(Y) protein expression in human
colorectal hyperplastic and neoplastic diseases. Int J Cancer.
91:147–151. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chiappetta G, Botti G, Monaco M, et al:
HMGA1 protein over-expression in human breast carcinomas:
correlation with ErbB2 expression. Clin Cancer Res. 10:7637–7644.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Meyer B, Loeschke S, Schultze A, et al:
HMGA2 overexpression in non-small cell lung cancer. Mol Carcinog.
46:503–511. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Masciullo V, Baldassarre G, Pentimalli F,
et al: HMGA1 protein over-expression is a frequent feature of
epithelial ovarian carcinomas. Carcinogenesis. 24:1191–1198. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tamimi Y, van der Poel HG, Denyn MM, et
al: Increased expression of high mobility group protein I(Y) in
high grade prostatic cancer determined by in situ hybridization.
Cancer Res. 53:5512–5516. 1993.PubMed/NCBI
|
|
22
|
Miyazawa J, Mitoro A, Kawashiri S, Chada
KK and Imai K: Expression of mesenchyme-specific gene HMGA2 in
squamous cell carcinomas of the oral cavity. Cancer Res.
64:2024–2029. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rho YS, Lim YC, Park IS, et al: High
mobility group HMGI(Y) protein expression in head and neck squamous
cell carcinoma. Acta Otolaryngol. 127:76–81. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dolde CE, Mukherjee M, Cho C and Resar LM:
HMG-I/Y in human breast cancer cell lines. Breast Cancer Res Treat.
71:181–191. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhong J, Cao RX, Zu XY, et al:
Identification and characterization of novel spliced variants of
PRMT2 in breast carcinoma. FEBS J. 279:316–335. 2012. View Article : Google Scholar
|
|
26
|
Welch DR, Fabra A and Nakajima M:
Transforming growth factor beta stimulates mammary adenocarcinoma
cell invasion and metastatic potential. Proc Natl Acad Sci USA.
87:7678–7682. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Derynck R and Zhang YE: Smad-dependent and
Smad-independent pathways in TGF-β family signalling. Nature.
425:577–584. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Moustakas A and Heldin CH: Non-Smad TGF-β
signals. J Cell Sci. 118:3573–3584. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Massimi I, Guerrieri F, Petroni M, Veschi
V, Truffa S, Screpanti I, Frati L, Levrero M, Gulino A and Giannini
G: The HMGA1 protoncogene frequently deregulated in cancer is a
transcriptional target of E2F1. Mol Carcinog. 52:526–534. 2013.
View Article : Google Scholar
|
|
30
|
Abe N, Watanabe T, Izumisato Y, et al:
High mobility group A1 is expressed in metastatic adenocarcinoma to
the liver and intrahepatic cholangiocarcinoma, but not in
hepatocellular carcinoma: its potential use in the diagnosis of
liver neoplasms. J Gastroenterol. 38:1144–1149. 2003. View Article : Google Scholar
|
|
31
|
Shah SN, Kerr C, Cope L, et al: HMGA1
reprograms somatic cells into pluripotent stem cells by inducing
stem cell transcriptional networks. PLoS One. 7:e485332012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang Q, Ji Y, Wang X and Evers BM:
Isolation and molecular characterization of the 5′-upstream region
of the human TRAIL gene. Biochem Biophys Res Commun. 276:466–471.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chan J, Prado-Lourenco L, Khachigian LM,
Bennett MR, Di Bartolo BA and Kavurma MM: TRAIL promotes VSMC
proliferation and neointima formation in a FGF-2-, Sp1
phosphorylation-, and NFkappaB-dependent manner. Circ Res.
106:1061–1071. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Flohr AM, Rogalla P, Bonk U, et al: High
mobility group protein HMGA1 expression in breast cancer reveals a
positive correlation with tumour grade. Histol Histopathol.
18:999–1004. 2003.PubMed/NCBI
|
